Baseline demographic and clinical characteristics
| Demographic | Value |
| Male (n,(%)) | 54,(58%) |
| Age (years) | 30.2±8.8 |
| ACHD follow-up (years) | 7.27±5.1 |
| Total follow-up (years) | 2809 |
| Average cardiac surgeries/procedures | 4.07±1.59 |
| Clinical characteristic, n (%) | |
| Fontan type | |
| Atriopulmonary | 28 (30.1) |
| Lateral tunnel | 35 (37.6) |
| Extracardiac | 29 (31.1) |
| AV regurgitation | |
| None/trivial | 41 (44.1) |
| Mild | 31 (33.3) |
| Moderate | 16 (17.2) |
| Severe | 2 (2.2) |
| Systemic ventricle | |
| LV | 69 (74.2) |
| RV | 21 (22.6) |
| Systolic dysfunction | |
| None | 50 (53.8) |
| Mild | 31 (33.3) |
| Moderate | 9 (9.7) |
| Severe | 1 (1.1) |
| Medication, n (%) | |
| ASA | 27 (29.0) |
| Warfarin | 49 (52.7) |
| DOAC | 3 (3.2) |
| LMWH | 2 (2.2) |
| ACEi | 33 (35.5) |
| BB | 29 (31.2) |
| Digoxin | 11 (11.8) |
| Diuretic | 16 (17.2) |
| Amiodarone | 5 (5.4) |
| Sotalol | 8 (8.6) |
ACEi, angiotensin converting enzyme inhibitor; ASA, acetylsalicylic acid; AV, atrioventricular; BB, beta blocker; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; LV, left ventricle; RV, right ventricle.